Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

Tiny lab-grown models of human immune systems are helping researchers understand why cancer patients struggle to fight ...

The team used synthetic hydrogels to recreate a microenvironment where B cells from human blood and tonsils can ... which failed to trigger the same response in cells from lymphoma survivors who ...

The combination of THIO and Libtayo has shown promising results among patients with advanced checkpoint inhibitor-resistant ...

“We're trying to target this pre-programmed subset of B cells,” Scharffenberger said. “If you're able to target them ...

Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...

Prince William County Public Schools cellphone pilot appears to be working well, school officials told the School Board at ...

DANYELZA specifically designed for children who have had an incomplete response to induction or relapsed therapy ... studying ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement ... including 51% of patients with ...